Comparison of the effects of immediate‐release omeprazole oral suspension, delayed‐release lansoprazole capsules and delayed‐release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night‐time GERD symptoms

Katz, Philip O.; Koch, Frauke K.; Ballard, Elizabeth D.; Bagin, Robert; Gautille, Theresa; Checani, Gregg; Hogan, Daniel L.; Pratha, Vijayalakshmi S.

doi:10.1111/j.1365-2036.2006.03191.x

Cited by 82 publications

(53 citation statements)

References 20 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The percentage of time with gastric pH >4 for the entire 24-h period was 43.6% after treatment with IR-OME vs. 59% with esomeprazole (p<0.001) and 27.8% with lansoprazole (p<0.001), when compared with both IR-OME and esomeprazole (Table 2). 14 This study further supports the longstanding suggestion that delayed release PPIs are not optimally effective when given at bedtime. Lansoprazole offered a slow onset of overnight control with little increase the next day.…”

Section: Immediate-release Omeprazolesupporting

confidence: 81%

“…13 An open-label, randomized, crossover study (N=54) compared intragastric pH with IR-OME suspension 40 mg, lansoprazole 30 mg, and esomeprazole 40 mg given at bedtime (10:00 P.M.) on an empty stomach for 7 days. 14 In the first half of the nighttime, intragastric pH >4 were higher after IR-OME compared to esomeprazole or lansoprazole (p<0.001, both comparisons). 15 Acid control with IR-OME was significantly better than lansoprazole (p< 0.001) and comparable to esomeprazole for the entire nighttime period.…”

Section: Immediate-release Omeprazolementioning

confidence: 91%

See 1 more Smart Citation

Proton Pump Inhibitors in the Management of GERD

Katz

Zavala

2010

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

Section: Immediate-release Omeprazolesupporting

confidence: 81%

Section: Immediate-release Omeprazolementioning

confidence: 91%

Proton Pump Inhibitors in the Management of GERD

Katz

Zavala

2010

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…There was significant difference in oesophagitis healing between group A & B. Katz P et al showed bed time IR-OMEP provided more rapid control of night time gastric pH and decrease in nocturnal acid break through compared to lansoprazole & esomeprazole. Nocturnal acid control with IR-OMEP was superior to lansoprazole & esomeprazole 27 .…”

Section: Gerd (N=69)mentioning

confidence: 86%

Role of Immediate Release and Delayed Release Omeprazole in Patients with Gastro Esophageal Reflux Disease

Rahman¹,

Ahmed

Jannat³

et al. 2017

Faridpur Med Coll J

View full text Add to dashboard Cite

to assess the efficacy of Immediate-release omeprazole (IR-OMEP) & Delayed-release Omeprazole (DR-OMEP) in relieving symptoms & healing of oesophagitis in GERD. All patients who fulfilled the inclusion criteria underwent upper gastrointestinal (UGI) endoscopy to be lebelled as nonerosive and erosive GERD. Among total 69 patients, 43 (62.3 %) had nonerosive and 26 (37.7 %) had erosive GERD. Patients were divided into group A (35) and group B (34) who received group A drugs (20 mg IR-OMEP bd) and group B drugs (20 mg DR-OMEP bd) from day 1-14 respectively. Then drugs were crossed over (group A: 20mg DR-OMEP bd; group B: 20 mg IR-OMEP bd) from day 15-28. Improvement of heartburn, regurgitation in each group were assessed in every week, during drug cross over and at the end and then compared between two groups. There was no significant difference in relieving heartburn and regurgitation between IR-OMEP and DR-OMEP either in erosive or nonerosive GERD (P>0.50). Patients with erosive GERD underwent UGI endoscopy at the end of treatment to see healing of esophagitis. Study showed significant healing of oesophagitis in group A after 4 weeks than group B (14%) (P<0.05) but there is no superiority of IR-OMEP over DR-OMEP in relieving symptoms of GERD.

show abstract

“…The enteric delayed-release dosage form of LPZ has been reported to be unable 4030 alai and lin to efficiently suppress nocturnal acid secretion in the event of gastroesophageal reflux disease. 6,7 Nocturnal acid breakthrough frequently occurs in patients with gastroesophageal reflux disease during the first half of the sleeping period, and affects sleep quality and daytime functioning. Eudragit ® RS100 and poly(lactic-co-glycolic acid) (PLGA) polymers have been used as drug carriers.…”

Section: Introductionmentioning

confidence: 99%

Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations

Alai¹,

Lin²

2015

IJN

View full text Add to dashboard Cite

The aim of this study was to develop nanoparticles for oral delivery of an acid-labile drug, lansoprazole (LPZ), for gastric ulcer therapy. LPZ-loaded positively charged Eudragit ® RS100 nanoparticles (ERSNPs-LPZ) and negatively charged poly(lactic-co-glycolic acid) nanoparticles (PLGANPs-LPZ) were prepared. The effect of charge on nanoparticle deposition in ulcerated and non-ulcerated regions of the stomach was investigated. The cellular uptake of nanoparticles in the intestine was evaluated in a Caco-2 cell model. The pharmacokinetic performance and ulcer healing response of LPZ-loaded nanoparticles following oral administration were evaluated in Wistar rats with induced ulcers. The prepared drug-loaded ERSNPs-LPZ and PLGANPs-LPZ possessed opposite surface charge (+38.5±0.3 mV versus −27.3±0.3 mV, respectively) and the particle size was around 200 nm with a narrow size distribution. The negatively charged PLGANPs adhered more readily to the ulcerated region (7.22%±1.21% per cm 2 ), whereas the positively charged ERSNPs preferentially distributed in the non-ulcerated region (8.29%±0.35% per cm 2 ). Both ERSNPs and PLGANPs were prominent uptake in Caco-2 cells, too. The nanoparticles sustained and prolonged LPZ concentrations up to 24 hours, and the half-life and mean residence time of LPZ were prolonged by 3.5-fold and 4.5-fold, respectively, as compared with LPZ solution. Oral administration of LPZ-loaded nanoparticles healed 92.6%–95.7% of gastric ulcers in Wistar rats within 7 days.

show abstract

Comparison of the effects of immediate‐release omeprazole oral suspension, delayed‐release lansoprazole capsules and delayed‐release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night‐time GERD symptoms

Abstract: SUMMARY BackgroundGastro-oesophageal reflux disease (GERD) patients on proton pump inhibitors before breakfast or dinner have acid recovery at night. Bedtime immediate-release omeprazole (IR-OME) demonstrated better control of nocturnal pH than pantoprazole before dinner.

Cited by 82 publications

References 20 publications

Proton Pump Inhibitors in the Management of GERD

Proton Pump Inhibitors in the Management of GERD

Role of Immediate Release and Delayed Release Omeprazole in Patients with Gastro Esophageal Reflux Disease

Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations

Contact Info

Product

Resources

About